Johnson & Johnson reported positive Phase 2 results for its drug nipocalimab in treating systemic lupus erythematosus and Sjögren's disease. Following this, the company acquired biotech firm Firefly Bio in a $1 billion cash deal to expand into KRAS-targeting degrader conjugates. Other significant industry activity included Incyte's $2 billion purchase of Vega Therapeutics and Galmed Pharmaceuticals' acquisition of Colospan to focus on gastrointestinal medical technology.
Johnson & Johnson released clinical data supporting the label expansion of Imaavy for a rare autoimmune disease, strengthening its biopharmaceutical growth prospects.
Read the full storyJ&J announced a $1 billion cash deal to acquire biotech firm Firefly Bio, marking a strategic move to expand its oncology drug portfolio.
The company met primary endpoints in its JASMINE study for SLE and Sjögren's disease, strengthening its pharmaceutical pipeline in high-growth autoimmune markets.